LOOMIS SAYLES & CO L P - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 41 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
LOOMIS SAYLES & CO L P ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2021$9,000
-76.3%
428
-74.2%
0.00%
Q1 2021$38,000
-77.2%
1,662
-75.4%
0.00%
Q4 2020$167,000
-46.5%
6,748
-10.4%
0.00%
Q3 2020$312,000
-13.6%
7,5290.0%0.00%
-100.0%
Q2 2020$361,000
-88.9%
7,529
-85.4%
0.00%
-85.7%
Q1 2020$3,250,000
-59.9%
51,617
-21.2%
0.01%
-50.0%
Q4 2019$8,113,000
+40.6%
65,465
-24.7%
0.01%
+27.3%
Q3 2019$5,771,000
-64.0%
86,969
-4.1%
0.01%
-63.3%
Q2 2019$16,049,000
-9.1%
90,645
+0.8%
0.03%
-14.3%
Q1 2019$17,664,000
+1.3%
89,889
-48.1%
0.04%
-14.6%
Q4 2018$17,442,000
-52.1%
173,055
-4.5%
0.04%
-42.3%
Q3 2018$36,378,000
-51.4%
181,264
-57.9%
0.07%
-53.0%
Q2 2018$74,803,000
+6.1%
430,234
-2.9%
0.15%
+1.3%
Q1 2018$70,482,000
-4.2%
442,975
-4.9%
0.15%
-2.6%
Q4 2017$73,545,000
+83.4%
465,862
+78.2%
0.15%
+75.9%
Q3 2017$40,097,000
+99.5%
261,383
+57.5%
0.09%
+85.1%
Q2 2017$20,098,000
+4.2%
166,005
-2.7%
0.05%
-2.1%
Q1 2017$19,291,000
+312.3%
170,563
+545.1%
0.05%
+336.4%
Q4 2016$4,679,00026,4380.01%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2020
NameSharesValueWeighting ↓
Silver Point Capital L.P. 57,420,000$44,527,0005.17%
Birch Grove Capital LP 10,003,000$7,934,0004.14%
PenderFund Capital Management Ltd. 9,605,000$9,491,0002.41%
Context Capital Management, LLC 9,887,000$7,671,0001.05%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 57,791,000$45,738,0000.90%
DeepCurrents Investment Group LLC 35,892,000$27,953,0000.74%
HIGHBRIDGE CAPITAL MANAGEMENT LLC 22,977,000$18,267,0000.70%
WHITEBOX ADVISORS LLC 23,150,000$17,847,0000.56%
ADVENT CAPITAL MANAGEMENT /DE/ 27,397,000$21,720,0000.46%
OAKTREE CAPITAL MANAGEMENT LP 19,435,000$15,079,0000.26%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders